Scarica l'app Stockscreener
1.97
0.51%
-0.01
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Allogene (NASDAQ: ALLO) exec plans sale of 29,697 shares - Stock Titan
Allogene Therapeutics, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Allogene (ALLO) Earnings Report: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Stock Move: Shares Finish 5.83% Down in the Available RecordEarnings Season Outlook - Vinanet
Allogene Therapeutics, Inc. (ALLO) Latest Stock News & Headlines - Yahoo Finance
Allogene Therapeutics, Inc. (ALLO) Stock Price, News, Quote & History - Yahoo Finance
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth - Moomoo
Allogene (ALLO) Q2 2026 Earnings Call Transcript - Yahoo Finance
Allogene Therapeutics (ALLO) Institutional Ownership 2026 $ALLO - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
ALLO Reiterated by Citizens -- Price Target Maintained at $6.00 - GuruFocus
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com Nigeria
Citizens reiterates Allogene stock rating on trial progress - Investing.com
Allogene Therapeutics (ALLO) Gains 3.54% as Shares Approach $2.15 ResistanceDemand Zone - vinanet.vn
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes - Stock Titan
Allogene Therapeutics (ALLO) Income Statement & Earnings - Moomoo
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy - CRISPR Medicine News
State Street Corp Expands Allogene Therapeutics (ALLO) Stake wit - GuruFocus
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says - marketscreener.com
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo
Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc. - marketbeat.com
Allogene Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... - Yahoo Finance
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlig - GuruFocus
Allogene Therapeutics Inc (ALLO) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Allogene Therapeutics (ALLO) Advances Clinical Pipeline Amidst H - GuruFocus
Allogene Therapeutics: Q2 Earnings Snapshot - AOL.com
Allogene Therapeutics Q2 2026: EPS beats, cash extends to 2029 - scanx.trade
Transcript : Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Allogene Therapeutics Announces Q2 2026 Financial Results Highlighting Reduced Losses, First Collaboration Revenue, and Significant Equity Raise - Kalkine Media
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast By Investing.com - Investing.com Canada
Allogene Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Therapeutics Q2 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast - Investing.com
Allogene TherapeuticsMay Offer Up To $500 Million In Securities - TradingView
Allogene Therapeutics Q2 Loss Narrows - marketscreener.com
Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss - marketscreener.com
Allogene posts $42.7 million Q2 loss as cash reaches $423.6 million - Quiver Quantitative
Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ALLO: ALPHA3 interim results highlight cema-cel's promise in LBCL and strong financial runway - tradingview.com
Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL - marketscreener.com
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update - The Manila Times
Allogene Therapeutics (ALLO) Edges Higher: CAR-T Developer Tests Key Resistance at $2.23Earnings Beat Stocks - Vinanet
Allogene Therapeutics Inc (ALLO) Q2 2026 Earnings Report Preview: What To Look For - finance.yahoo.com
Allogene Therapeutics, Inc. expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Allogene Therapeutics (ALLO) stake: Belldegrun group reports 3.9% ownership - Stock Titan
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene - Stock Titan
Allogene Therapeutics, Inc. (ALLO) Options Chain - Yahoo Finance
Allogene Therapeutics (ALLO) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
William Blair Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo
Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12 - scanx.trade
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):